Therapeutics Targeting Drivers of Thoracic Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and Mouse Models.

Thoracic aortic diseases, including aneurysms and dissections of the thoracic aorta, are a major cause of morbidity and mortality. Risk factors for thoracic aortic disease include increased hemodynamic forces on the ascending aorta, typically due to poorly controlled hypertension, and heritable genetic variants. The altered genes predisposing to thoracic aortic disease either disrupt smooth muscle cell (SMC) contraction or adherence to an impaired extracellular matrix, or decrease canonical transforming growth factor beta (TGF-β) signaling. Paradoxically, TGF-β hyperactivity has been postulated to be the primary driver for the disease. More recently, it has been proposed that the response of aortic SMCs to the hemodynamic load on a structurally defective aorta is the primary driver of thoracic aortic disease, and that TGF-β overactivity in diseased aortas is a secondary, unproductive response to restore tissue function. The engineering of mouse models of inherited aortopathies has identified potential therapeutic agents to prevent thoracic aortic disease.

[1]  D. Milewicz,et al.  Loss of Smooth Muscle &agr;-Actin Leads to NF-&kgr;B–Dependent Increased Sensitivity to Angiotensin II in Smooth Muscle Cells and Aortic Enlargement , 2017, Circulation research.

[2]  J. Humphrey,et al.  Differential ascending and descending aortic mechanics parallel aneurysmal propensity in a mouse model of Marfan syndrome. , 2016, Journal of biomechanics.

[3]  K. Costa,et al.  Losartan Attenuates Degradation of Aorta and Lung Tissue Micromechanics in a Mouse Model of Severe Marfan Syndrome , 2016, Annals of Biomedical Engineering.

[4]  A. Evangelista,et al.  Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. , 2016, European heart journal.

[5]  Corey L. Reynolds,et al.  FOXE3 mutations predispose to thoracic aortic aneurysms and dissections. , 2016, The Journal of clinical investigation.

[6]  J. Shendure,et al.  LOX Mutations Predispose to Thoracic Aortic Aneurysms and Dissections. , 2016, Circulation research.

[7]  Wanjun Liu,et al.  Association between Diabetes and Risk of Aortic Dissection: A Case-Control Study in a Chinese Population , 2015, PloS one.

[8]  T. David,et al.  Outcomes of Aortic Valve-Sparing Operations in Marfan Syndrome. , 2015, Journal of the American College of Cardiology.

[9]  Jennifer E Van Eyk,et al.  A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome , 2015, eLife.

[10]  F. Tubach,et al.  Marfan Sartan: a randomized, double-blind, placebo-controlled trial. , 2015, European heart journal.

[11]  Hailong Lu,et al.  Vascular disease-causing mutation R258C in ACTA2 disrupts actin dynamics and interaction with myosin , 2015, Proceedings of the National Academy of Sciences.

[12]  J. Humphrey,et al.  Role of mechanotransduction in vascular biology: focus on thoracic aortic aneurysms and dissections. , 2015, Circulation research.

[13]  B. Wentworth,et al.  Dimorphic Effects of Transforming Growth Factor-&bgr; Signaling During Aortic Aneurysm Progression in Mice Suggest a Combinatorial Therapy for Marfan Syndrome , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[14]  D. Navajas,et al.  Vascular Smooth Muscle Cell Phenotypic Changes in Patients With Marfan Syndrome , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[15]  A. Zwinderman,et al.  Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome , 2015, Circulation. Cardiovascular genetics.

[16]  F. Blankenberg,et al.  Enhanced Caspase Activity Contributes to Aortic Wall Remodeling and Early Aneurysm Development in a Murine Model of Marfan Syndrome , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[17]  M. Gross,et al.  MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections. , 2014, American journal of human genetics.

[18]  S. Colan,et al.  Atenolol versus losartan in children and young adults with Marfan's syndrome. , 2014, The New England journal of medicine.

[19]  J. Coselli,et al.  Early and 1-year outcomes of aortic root surgery in patients with Marfan syndrome: a prospective, multicenter, comparative study. , 2014, The Journal of thoracic and cardiovascular surgery.

[20]  J. Humphrey,et al.  Dysfunctional Mechanosensing in Aneurysms , 2014, Science.

[21]  Kevin D Costa,et al.  Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. , 2014, The Journal of clinical investigation.

[22]  D. Valenti,et al.  Diabetics are less likely to develop thoracic aortic dissection: a 10-year single-center analysis. , 2014, Annals of vascular surgery.

[23]  Henk A Marquering,et al.  Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. , 2013, European heart journal.

[24]  M. Rieder,et al.  Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. , 2013, American journal of human genetics.

[25]  D. Milewicz,et al.  Smooth muscle hyperplasia due to loss of smooth muscle α-actin is driven by activation of focal adhesion kinase, altered p53 localization and increased levels of platelet-derived growth factor receptor-β. , 2013, Human molecular genetics.

[26]  D. Rifkin,et al.  Unchaining the beast; insights from structural and evolutionary studies on TGFβ secretion, sequestration, and activation. , 2013, Cytokine & growth factor reviews.

[27]  Amitava Banerjee,et al.  Population-Based Study of Incidence and Outcome of Acute Aortic Dissection and Premorbid Risk Factor Control: 10-Year Results From the Oxford Vascular Study , 2013, Circulation.

[28]  Victoria P. Le,et al.  Angiotensin-Converting Enzyme–Induced Activation of Local Angiotensin Signaling Is Required for Ascending Aortic Aneurysms in Fibulin-4–Deficient Mice , 2013, Science Translational Medicine.

[29]  J. Stull,et al.  Signaling through Myosin Light Chain Kinase in Smooth Muscles* , 2013, The Journal of Biological Chemistry.

[30]  D. Rifkin,et al.  Specificity of latent TGF‐β binding protein (LTBP) incorporation into matrix: Role of fibrillins and fibronectin , 2012, Journal of cellular physiology.

[31]  E. Fishman,et al.  Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm , 2012, Nature Genetics.

[32]  Jay Shendure,et al.  TGFB2 loss of function mutations cause familial thoracic aortic aneurysms and acute aortic dissections associated with mild systemic features of the Marfan syndrome , 2012, Nature Genetics.

[33]  D. Milewicz,et al.  Diabetes and Reduced Risk for Thoracic Aortic Aneurysms and Dissections: A Nationwide Case-Control Study , 2012, Journal of the American Heart Association.

[34]  F. Tubach,et al.  Aortic Event Rate in the Marfan Population: A Cohort Study , 2012, Circulation.

[35]  S. Leal,et al.  Genome-wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1 , 2011, Nature Genetics.

[36]  D. Milewicz,et al.  Susceptibility to acute thoracic aortic dissections in patients dying outside the hospital: an autopsy study. , 2011, American heart journal.

[37]  P. J. van der Spek,et al.  Impaired Vascular Contractility and Aortic Wall Degeneration in Fibulin-4 Deficient Mice: Effect of Angiotensin II Type 1 (AT1) Receptor Blockade , 2011, PloS one.

[38]  T. Walz,et al.  Latent TGF-β structure and activation , 2011, Nature.

[39]  S. Leal,et al.  Recurrent Chromosome 16p13.1 Duplications Are a Risk Factor for Aortic Dissections , 2011, PLoS genetics.

[40]  D. Milewicz,et al.  TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections. , 2010, Cardiovascular research.

[41]  S. Shete,et al.  Mutations in myosin light chain kinase cause familial aortic dissections. , 2010, American journal of human genetics.

[42]  D. Milewicz,et al.  De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction , 2010, American journal of medical genetics. Part A.

[43]  David M. Williams,et al.  2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, Ame , 2010, Journal of the American College of Cardiology.

[44]  L. Rénia,et al.  TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. , 2010, The Journal of clinical investigation.

[45]  K E Porter,et al.  Diabetes and the abdominal aortic aneurysm. , 2010, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[46]  J. Coselli,et al.  Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations , 2009, Journal of Medical Genetics.

[47]  Robert K. Yu,et al.  Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. , 2009, American journal of human genetics.

[48]  H. Dietz,et al.  p38 MAPK Is an Early Determinant of Promiscuous Smad2/3 Signaling in the Aortas of Fibrillin-1 (Fbn1)-null Mice* , 2009, Journal of Biological Chemistry.

[49]  D. Milewicz,et al.  Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. , 2008, Annual review of genomics and human genetics.

[50]  M. Radomski,et al.  Long-Term Doxycycline Is More Effective Than Atenolol to Prevent Thoracic Aortic Aneurysm in Marfan Syndrome Through the Inhibition of Matrix Metalloproteinase-2 and -9 , 2008, Circulation research.

[51]  B. Hinz,et al.  Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix , 2007, The Journal of cell biology.

[52]  D. Milewicz,et al.  MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. , 2007, Human molecular genetics.

[53]  K. Eagle,et al.  Aortic Diameter ≥5.5 cm Is Not a Good Predictor of Type A Aortic Dissection: Observations From the International Registry of Acute Aortic Dissection (IRAD) , 2007, Circulation.

[54]  W. Berger,et al.  Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome , 2007, Human Genetics.

[55]  Katherine H Kim,et al.  Fibulin-4: a novel gene for an autosomal recessive cutis laxa syndrome. , 2006, American journal of human genetics.

[56]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[57]  A. Lalande,et al.  Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus , 2006, Nature Genetics.

[58]  Wolfram Kress,et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.

[59]  S. Ledbetter,et al.  Neutralization of transforming growth factor-β attenuates hypertension and prevents renal injury in uremic rats , 2005, Journal of hypertension.

[60]  M. Crepeau,et al.  Aortic aneurysmal disease and cutis laxa caused by defects in the elastin gene , 2005, Journal of Medical Genetics.

[61]  J. Egido,et al.  Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor-β–Independent Mechanism , 2005, Circulation.

[62]  水口 剛.  Heterozygous TGFBR2 mutations in Marfan syndrome , 2005 .

[63]  Rossella Fattori,et al.  Gender-Related Differences in Acute Aortic Dissection , 2004, Circulation.

[64]  R. Lechleider,et al.  Transforming Growth Factor-β–Induced Differentiation of Smooth Muscle From a Neural Crest Stem Cell Line , 2004 .

[65]  J. Elefteriades.  Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. , 2002, The Annals of thoracic surgery.

[66]  V. Gott,et al.  Aortic root replacement in 271 Marfan patients: a 24-year experience. , 2002, The Annals of thoracic surgery.

[67]  M. Entman,et al.  Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[68]  H. Dietz,et al.  Phenotypic Alteration of Vascular Smooth Muscle Cells Precedes Elastolysis in a Mouse Model of Marfan Syndrome , 2001, Circulation research.

[69]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[70]  S. Fisher,et al.  Higher prevalence of abdominal aortic aneurysms in patients with carotid stenosis but without diabetes. , 1999, Surgery.

[71]  J. Elefteriades,et al.  Familial patterns of thoracic aortic aneurysms. , 1999, Archives of surgery.

[72]  R. E. Luna,et al.  Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. , 1998, Circulation.

[73]  D. Milewicz,et al.  Reduced penetrance and variable expressivity of familial thoracic aortic aneurysms/dissections. , 1998, The American journal of cardiology.

[74]  R. Hynes,et al.  Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.

[75]  G. Boivin,et al.  TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. , 1997, Development.

[76]  D J Ballard,et al.  Prevalence and Associations of Abdominal Aortic Aneurysm Detected through Screening , 1997, Annals of Internal Medicine.

[77]  J. Elefteriades,et al.  What is the appropriate size criterion for resection of thoracic aortic aneurysms? , 1997, The Journal of thoracic and cardiovascular surgery.

[78]  J. Coselli,et al.  Familial thoracic aortic dilatations and dissections: a case control study. , 1997, Journal of vascular surgery.

[79]  R. Timpl,et al.  Cell adhesion and integrin binding to recombinant human fibrillin‐1 , 1996, FEBS letters.

[80]  J. Coselli,et al.  Marfan syndrome. Long-term survival and complications after aortic aneurysm repair. , 1995, Circulation.

[81]  N. Kouchoukos,et al.  Life expectancy in the Marfan syndrome. , 1995, The American journal of cardiology.

[82]  E. Murphy,et al.  Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.

[83]  C. Junien,et al.  Autosomal dominant Marfan-like connective-tissue disorder with aortic dilation and skeletal anomalies not linked to the fibrillin genes. , 1993, American journal of human genetics.

[84]  W. S. Lee,et al.  Role of transforming growth factor-beta 1 in the cellular growth response to angiotensin II. , 1993, Hypertension.

[85]  G. Gibbons,et al.  Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. , 1992, The Journal of clinical investigation.

[86]  R. Pyeritz,et al.  Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. , 1990, The New England journal of medicine.

[87]  K. Peterson,et al.  Familial aortic dissecting aneurysm. , 1989, Journal of the American College of Cardiology.

[88]  C. Simpson,et al.  Effect of Hydralazine on Aortic Rupture Induced by B‐Aminopropionitrile in Turkeys , 1982, Circulation.

[89]  V. McKusick,et al.  Life expectancy and causes of death in the Marfan syndrome. , 1972, The New England journal of medicine.

[90]  H. Bentall,et al.  A technique for complete replacement of the ascending aorta , 1968, Thorax.

[91]  C. Simpson,et al.  The Use of Propranolol for the Protection of Turkeys From the Development of β-Aminopropionitrile-Induced Aortic Ruptures , 1968, Angiology.

[92]  J. Sautter,et al.  Natural Dissecting Aneurysm (Aortic Rupture) and Blood Pressure in the Turkey , 1967, Nature.

[93]  R. C. Seelman,et al.  TREATMENT OF DISSECTING ANEURYSMS OF THE AORTA WITHOUT SURGERY. , 1965, The Journal of thoracic and cardiovascular surgery.

[94]  V. McKusick,et al.  The Cardiovascular Aspects of Marfan's Syndrome: A Heritable Disorder of Connective Tissue , 1955, Circulation.

[95]  G. Moneta.  Rare Copy Number Variants Disrupt Genes Regulating Vascular Smooth Muscle Cell Adhesion and Contractility in Sporadic Thoracic Aortic Aneurysms and Dissections , 2011 .

[96]  C. van Breemen,et al.  Vasomotor dysfunction in the thoracic aorta of Marfan syndrome is associated with accumulation of oxidative stress. , 2010, Vascular pharmacology.

[97]  Souvik Sen,et al.  2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, Ame , 2010, Circulation.

[98]  B. Baxter,et al.  Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. , 2008, Journal of vascular surgery.

[99]  Robert K. Yu,et al.  Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections (vol 39, pg 1488, 2007) , 2008 .

[100]  Jeffery A. Jones,et al.  xpression of matrix metalloproteinases and endogenous nhibitors within ascending aortic aneurysms of patients ith bicuspid or tricuspid aortic valves , 2007 .

[101]  R. Lechleider,et al.  Transforming growth factor-beta-induced differentiation of smooth muscle from a neural crest stem cell line. , 2004, Circulation research.

[102]  R. Hynes,et al.  Thrombospondin-1 is a major activator of TGF-beta1 in vivo. , 1998, Cell.

[103]  E. Davis,et al.  Smooth muscle cell to elastic lamina connections in developing mouse aorta. Role in aortic medial organization. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[104]  P. Byers,et al.  Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts. , 1992, The Journal of clinical investigation.